Hope everyone had a fantastic Christmas weekend. Last month there were quite a few large small molecules, including three macrocycles. Quite a few of these molecules would’ve made for a decent synthesis PhD project! Some highlights include a cryo-EM structure …
Hope everyone is having a great US Thanksgiving week. This month’s update features quite a few contributions from international companies, including three from Bayer in Germany, a double soft drug from Leo Pharma in Denmark, and others from sites in …
This was a loaded month for pioneering drug discovery programs! Among the highlights are a reversible-covalent inhibitor from Novartis, the hotly followed SHP2 inhibitor from Novartis, several innovative compounds from Pfizer including an oral GLP-1R agonist with a cryo-EM structure, …
Plenty of eye-opening material was published this August! Among this month’s highlights are a small molecule with twice-a-year dosing from Gilead, a non-classical C-H—O hydrogen-bonding kinase inhibitor from Pfizer, an E1 ligase inhibitor with a cool substrate-assisted covalent mechanism from …
Many more modalities, mechanisms, screening strategies, and interesting chemical motifs appeared from the drug discovery community in July. This time we have a compound from a DNA-encoded library screen, some compounds derived from phenotypic screens, and a starting point identified …
The drug discovery community kicked off the summer with a lot of very interesting molecules published in June. After ~50 molecular highlights so far this year, you’d think we’ve seen it all, but there were again numerous fascinating chemical motifs, …